Compare HCA Health Inc (HCA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs TransMedics Group Inc — how do they compare? HCA Health Inc trades at $448.85 (market cap $96.35B), while TransMedics Group Inc trades at $77.47 (market cap $2.74B). The key difference: HCA Health Inc is far larger — about 35.2× TransMedics Group Inc's market cap, and HCA Health Inc pays a 0.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and TransMedics Group Inc for 24 Days on average.
| HCA | TMDX | |
|---|---|---|
Market Cap | $96.35B | $2.74B |
Volume | 1,079,453 | 949,331 |
Sector | Health | Health |
52-Week High | $545.13 | $150.42 |
52-Week Low | $361.32 | $61.99 |
Typical Hold Time | 76 Days | 24 Days |
Enterprise Value | $146.88B | $3.13B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
